These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38555760)

  • 21. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
    Gambrell RD
    Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Menopause and cardiovascular disease: the evidence.
    Rosano GM; Vitale C; Marazzi G; Volterrani M
    Climacteric; 2007 Feb; 10 Suppl 1():19-24. PubMed ID: 17364594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adipocytokine and ghrelin levels in relation to cardiovascular disease risk factors in women at midlife: longitudinal associations.
    Wildman RP; Mancuso P; Wang C; Kim M; Scherer PE; Sowers MR
    Int J Obes (Lond); 2008 May; 32(5):740-8. PubMed ID: 18180784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic features of menopausal and postmenopausal applicants for life insurance.
    Schiefeling M
    J Insur Med; 1996; 28(1):27-34. PubMed ID: 10172866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualizing hormone-therapy according to cardiovascular risk.
    Shoupe D
    Minerva Ginecol; 2013 Dec; 65(6):631-9. PubMed ID: 24346251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study.
    de Kat AC; Dam V; Onland-Moret NC; Eijkemans MJ; Broekmans FJ; van der Schouw YT
    BMC Med; 2017 Jan; 15(1):2. PubMed ID: 28049531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intersection between gonadal function and vascular aging in women.
    Moreau KL
    J Appl Physiol (1985); 2018 Dec; 125(6):1881-1887. PubMed ID: 30212304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can menopause be considered an independent risk factor for cardiovascular disease?
    Mercuro G; Zoncu S; Cherchi A; Rosano GM
    Ital Heart J; 2001 Oct; 2(10):719-27. PubMed ID: 11721715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Menopause.
    Davis SR; Lambrinoudaki I; Lumsden M; Mishra GD; Pal L; Rees M; Santoro N; Simoncini T
    Nat Rev Dis Primers; 2015 Apr; 1():15004. PubMed ID: 27188659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular health and the menopause, metabolic health.
    Anagnostis P; Stevenson JC
    Best Pract Res Clin Endocrinol Metab; 2024 Jan; 38(1):101781. PubMed ID: 37183085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [MENOPAUSE AND CARDIOVASCULAR RISK.].
    Gavrailova D; Dimitrova A; Hadgideleva D
    Akush Ginekol (Sofiia); 2016; 55(4):46-51. PubMed ID: 29370494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of the Vasomotor Symptoms of Menopause: Twofers in Your Clinical Toolbox.
    Kling JM; Stuenkel CA; Faubion SS
    Mayo Clin Proc; 2024 Jul; 99(7):1142-1148. PubMed ID: 38960498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is menopause a risk factor for ischemic heart disease in women?].
    Leuzzi C; Marzullo R; Modena MG
    G Ital Cardiol (Rome); 2012 Jun; 13(6):401-6. PubMed ID: 22622118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular disease in menopause: does the obstetric history have any bearing?
    Mahendru AA; Morris E
    Menopause Int; 2013 Sep; 19(3):115-20. PubMed ID: 23940129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
    Genazzani AR; Monteleone P; Giannini A; Simoncini T
    Hum Reprod Update; 2021 Oct; 27(6):1115-1150. PubMed ID: 34432008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Menopause and cardiometabolic diseases: What we (don't) know and why it matters.
    Roa-Díaz ZM; Raguindin PF; Bano A; Laine JE; Muka T; Glisic M
    Maturitas; 2021 Oct; 152():48-56. PubMed ID: 34674807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
    Anagnostis P; Paschou SA; Katsiki N; Krikidis D; Lambrinoudaki I; Goulis DG
    Curr Vasc Pharmacol; 2019; 17(6):564-572. PubMed ID: 29984659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body composition and cardiometabolic health across the menopause transition.
    Marlatt KL; Pitynski-Miller DR; Gavin KM; Moreau KL; Melanson EL; Santoro N; Kohrt WM
    Obesity (Silver Spring); 2022 Jan; 30(1):14-27. PubMed ID: 34932890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The menopausal transition period and cardiovascular risk.
    Mehta JM; Manson JE
    Nat Rev Cardiol; 2024 Mar; 21(3):203-211. PubMed ID: 37752349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Where do we currently stand with advice on hormone replacement therapy for women?
    Bozkurt B
    Methodist Debakey Cardiovasc J; 2010 Nov-2011 Jan; 6(4):21-5. PubMed ID: 21088655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.